Clinical Trial: Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction Adenocarcinoma

U.S., June 12 -- ClinicalTrials.gov registry received information related to the study (NCT07643623) titled 'Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction Adenocarcinoma' on June 04.

Brief Summary: This is a Randomized, Double-Blind, Phase II/III Clinical Study of the Efficacy and Safety of Sintilimab Combined with Chemotherapy With or Without Ipilimumab N01 in Perioperative Treatment of Resectable Gastric/Gastroesophageal Junction Adenocarcinoma.

Study Start Date: June 15

Study Type: INTERVENTIONAL

Condition: Resectable Gastric/Gastroesophageal Junction Adenocarcinoma

Intervention: DRUG: tegafur, Gimeracil and Oteracil ...